CRNX:NSD-Crinetics Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 50.58

Change

+0.13 (+0.26)%

Market Cap

USD 4.25B

Volume

0.68M

Analyst Target

USD 36.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing CRNX

SBIO ALPS Medical Breakthrough.. 2.71 % 0.50 %

+0.12 (+0.08%)

USD 0.12B
MMSC First Trust Multi-Manager.. 1.23 % 0.00 %

+0.02 (+0.08%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 42.16% 81% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.16% 81% B- 88% B+
Trailing 12 Months  
Capital Gain 72.39% 82% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.39% 82% B 90% A-
Trailing 5 Years  
Capital Gain 234.30% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 234.30% 90% A- 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 35.18% 80% B- 86% B+
Dividend Return 35.18% 80% B- 86% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 62.54% 52% F 28% F
Risk Adjusted Return 56.26% 96% N/A 82% B
Market Capitalization 4.25B 94% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector